Get all your news in one place
100’s of premium titles. One news app. Zero ads. Just $10 per month.
Benzinga

Recap: Revance Therapeutics Q1 Earnings

Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Earnings

Revance Therapeutics missed estimated earnings by 3.3%, reporting an EPS of $-0.94 versus an estimate of $-0.91.

Revenue was up $11.96 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.09 which was followed by a 12.01% increase in the share price the next day.

Here's a look at Revance Therapeutics's past performance:

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -1.02 -1.15 -1.05 -1.09
EPS Actual -0.93 -1.10 -1.07 -1.08
Revenue Estimate 24.27M 20.29M 15.48M 10.98M
Revenue Actual 25.95M 19.75M 18.80M 13.30M

To track all earnings releases for Revance Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.